Early Prediction of Systemic Inflammatory Response Syndrome in Infants Using Procalcitonin and D-Dimer

Ergasheva Madina Narimanovna

doi:10.51699/cajmns.v7i1.3052

Ergasheva Madina Narimanovna Department of Hospital Paediatrics, Traditional Medicine, Tashkent Medical State University

DOI: https://doi.org/10.51699/cajmns.v7i1.3052

Keywords: systemic inflammatory response syndrome, infants, early diagnosis, predictive markers, D-dimer, procalcitonin, C-reactive protein, sepsis

Abstract

Systemic Inflammatory Response Syndrome (SIRS) in infants is a life-threatening disease because of the immaturity of immune, cardiovascular and metabolic control systems during the first year of life. Systematic inflammatory response is especially difficult to detect at an early age, since the classical clinical manifestations, including fever, leukocytosis or hemodynamic instability, may be absent or poorly manifested in young children. Late diagnosis means that the patients have an increased risk of transition to serious complications, such as sepsis, dysfunction of multiple organs, and cardiovascular failure. The paper is devoted to the creation of a predictive model of the early diagnosis of SIRS in infants with the assistance of a complex of clinical risk factors and lab biomarkers. Emphasis is placed on the presence of inflammatory and coagulation markers like C- C-reactive protein, procalcitonin and D-dimer that indicate the severity of general inflammation and endothelial impairment. Perinatal history, maternal health, and neonatal analysis of the characteristics enable the identification of infants at risk of developing systemic inflammatory reactions. The suggested model of prognostics offers a sensible and objective instrument of risk stratification in infants with infectious diseases, especially pneumonia, at an early stage. Early identification of high-risk patients helps to start specialised therapeutic interventions promptly, such as close monitoring, antimicrobial treatment, and supportive care. The adoption of the mentioned predictive approach into clinical practice can help minimise infant mortality, avoid severe complications, and optimise the treatment approaches in paediatric intensive care units.

References

B. Goldstein, B. Giroir, and A. Randolph, “International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics,” Pediatric Critical Care Medicine, vol. 6, no. 1, pp. 2–8, 2005, doi: 10.1097/01.PCC.0000149131.72248.E6.

J. L. Wynn and H. R. Wong, “Pathophysiology and treatment of septic shock in neonates,” Clinics in Perinatology, vol. 37, no. 2, pp. 439–479, 2010, doi: 10.1016/j.clp.2010.04.002.

N. Hofer, W. Müller, and B. Resch, “C-reactive protein and procalcitonin for the diagnosis of neonatal sepsis: A literature review,” Pediatrics, vol. 130, no. 4, pp. e1047–e1055, 2012, doi: 10.1542/peds.2012-0342.

M. Levi and T. van der Poll, “Coagulation and sepsis,” Thrombosis Research, vol. 149, pp. 38–44, 2017, doi: 10.1016/j.thromres.2016.11.007.

K. A. Simonsen, A. L. Anderson-Berry, S. F. Delair, and H. D. Davies, “Early-onset neonatal sepsis,” Clinical Microbiology Reviews, vol. 27, no. 1, pp. 21–47, 2014, doi: 10.1128/CMR.00031-13.

World Medical Association, “World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects,” JAMA, vol. 310, no. 20, pp. 2191–2194, 2013, doi: 10.1001/jama.2013.281053.

A. L. Shane, P. J. Sánchez, and B. J. Stoll, “Neonatal sepsis,” The Lancet, vol. 390, no. 10104, pp. 1770–1780, 2017, doi: 10.1016/S0140-6736(17)31002-4.

R. M. Kliegman, J. W. St Geme, N. J. Blum, S. S. Shah, R. C. Tasker, and K. M. Wilson, Nelson Textbook of Pediatrics, 21st ed. Philadelphia, PA, USA: Elsevier, 2020, doi: 10.1016/C2018-0-01519-4.

M. Meisner, “Procalcitonin: Experience with a new diagnostic tool for bacterial infection and systemic inflammation,” Journal of Laboratory Medicine, vol. 23, no. 5, pp. 263–272, 1999, doi: 10.1515/JLM.1999.042.

J. E. Lawn, S. Cousens, and J. Zupan, “4 million neonatal deaths: When? Where? Why?” The Lancet, vol. 365, no. 9462, pp. 891–900, 2005, doi: 10.1016/S0140-6736(05)71048-5.

Y. Singh et al., “Cardiovascular dysfunction in neonates with sepsis,” Journal of Perinatology, vol. 38, no. 6, pp. 799–807, 2018, doi: 10.1038/s41372-018-0079-7.

M. Stocker et al., “Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis,” The Lancet, vol. 390, no. 10097, pp. 871–881, 2017, doi: 10.1016/S0140-6736(17)31444-7.

J. R. Rodelo et al., “D-dimer is a significant prognostic factor in patients with suspected infection and sepsis,” American Journal of Emergency Medicine, vol. 30, no. 9, pp. 1991–1999, 2012, doi: 10.1016/j.ajem.2012.04.033.

H. Hagberg et al., “The role of inflammation in perinatal brain injury,” Nature Reviews Neurology, vol. 11, no. 4, pp. 192–208, 2015, doi: 10.1038/nrneurol.2015.13.

L. J. Schlapbach and N. Kissoon, “Defining pediatric sepsis,” JAMA Pediatrics, vol. 172, no. 4, pp. 312–314, 2018, doi: 10.1001/jamapediatrics.2017.5208.

S. M. Opal and T. van der Poll, “Endothelial barrier dysfunction in septic shock,” Journal of Internal Medicine, vol. 277, no. 3, pp. 277–293, 2015, doi: 10.1111/joim.12331.

F. A. Bozza et al., “Cytokine profiles as markers of disease severity in sepsis,” Shock, vol. 28, no. 3, pp. 268–273, 2007, doi: 10.1097/SHK.0b013e318048c87a.

D. C. Angus and T. van der Poll, “Severe sepsis and septic shock,” New England Journal of Medicine, vol. 369, no. 9, pp. 840–851, 2013, doi: 10.1056/NEJMra1208623